MAP2K7 and cutaneous melanoma: In this context, an advanced DDI detection software (Drug-PIN, V. 2/23) was used to assess the DDIs in a retrospective cohort of 177 patients with metastatic BRAF-mutated cutaneous melanoma treated with BRAF and MEK inhibitors.